Two $150 Million Biotech IPOs, One From Boston, Test the Fall Window

Two more drug developers are lining up to test investor appetite for biotech listings. Aspen Neuroscience, a San Diego company developing a cell therapy for Parkinson’s disease, and Bambusa Therapeutics, a two-year-old Boston immunology startup, launched initial public offering roadshows on Monday, Oct. 26, each seeking roughly $150 million on the Nasdaq, according to Reuters. Renaissance Capital listed Bambusa as expected to price during the week of Oct. 26. As of Thursday morning, neither company had announced final terms.

The deals arrive at an awkward macro moment. The Federal Reserve held its benchmark rate at 3.75% to 4.00% on Wednesday, with two officials dissenting in favor of an immediate hike, CNBC reported. Yet biotech has been one of the few sectors keeping the IPO calendar busy this fall, and Paxton-Digital has tracked a run of recent pricings, including Lycia Therapeutics’ $318 million debut and Iambic’s $150 million offering.

The terms

Both companies are marketing about 9.38 million shares at $15 to $17 apiece, implying gross proceeds of about $150 million at the $16 midpoint, according to Reuters and IPOScoop. The similarity ends there.

Aspen Neuroscience (proposed ticker ASPE) would carry a market value of about $465 million at the midpoint, IPOScoop calculated. Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank and Oppenheimer are the bookrunners. Founded in 2018, the company had about 120 employees at the time of filing, per Renaissance Capital.

Bambusa Therapeutics (proposed ticker BBTX) is valued far higher relative to its age. Renaissance Capital put its fully diluted market value at about $837 million at the midpoint. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are leading the deal.

What each company is building

Aspen’s lead candidate, sasineprocel, is an investigational, single-dose autologous cell therapy for sporadic Parkinson’s disease. The approach uses a patient’s own cells, reprogrammed into induced pluripotent stem cells and then into dopamine-producing neurons, to replace the cells the disease destroys. The therapy is in the Phase 1/2a ASPIRO trial in patients with mid-stage to moderately advanced disease, and the company expects to begin dosing in a Phase 3 trial in the second half of 2027, according to IPOScoop. Aspen reported a net loss of about $66.8 million with no product revenue for the 12 months ended June 30, 2026.

Bambusa, founded in 2024, develops long-acting bispecific antibodies, single molecules designed to block two inflammatory signals at once. Its lead program, BBT001, targets IL-4Rα and IL-31 and is in Phase 1 for atopic dermatitis, with initial proof-of-concept data reported in July 2026, as well as a Phase 2a study in China for chronic spontaneous urticaria. A second program, BBT002, targets IL-4Rα and IL-5 and is in early-stage studies for COPD, asthma and chronic rhinosinusitis with nasal polyps. Two preclinical programs target inflammatory bowel disease and B-cell-driven autoimmune disease. Renaissance Capital reports that Bambusa’s lead assets were licensed from BioNTech’s China-based subsidiary, a structure that has become common as U.S. startups in-license molecules discovered in China.

Reading the market

Reuters reported that more than half a dozen biotech companies have gone public in New York since September, and that Rezera and Windward Bio filed for IPOs the prior week. Lukas Muehlbauer, an associate at IPO research firm IPOX, told the news agency that “higher financing costs remain a challenge” for companies far from revenue, while noting that clinical milestones can still reward investors in an uncertain economy.

The two deals offer a clean contrast. Aspen is a later-stage story in a high-risk field: cell therapies for Parkinson’s have a long history of promising early data and hard manufacturing problems. Bambusa is earlier-stage but sits in one of the most commercially proven areas of drug development, building on validated targets such as IL-4Rα, the pathway behind blockbuster eczema drugs.

Paxton-Digital’s Take

Paxton-Digital views this pair as a useful read on what public investors will pay for, and at what stage. A Bambusa valuation near the top of its range would confirm that investors still prize validated targets and in-licensed assets with a fast path to proof-of-concept data, even for a company founded two years ago. A strong Aspen book would suggest appetite is broadening to more complex modalities. If either deal prices below range or is downsized, Paxton-Digital would read that as a sign that the window is narrowing, at least until after next week’s midterm elections and the Fed’s December decision. For Boston, a successful Bambusa debut would add another young company to the region’s public biotech roster.

What it means for you

• IPO prices are set the night before trading, and first-day moves can be large in both directions; the range is not a promise.
• Clinical-stage biotechs have no product revenue, so their value rests on trial results and future financing.
• Look for lock-up dates in the final prospectus; insider selling often arrives about six months after listing.
• Patients and caregivers following Parkinson’s research can track the ASPIRO trial on ClinicalTrials.gov regardless of the stock.

Discussion

1. Should young biotechs built on in-licensed assets command higher valuations than companies with homegrown science?
2. Does a Fed on hold, with dissents favoring a hike, change how you view early-stage biotech risk?
3. What would a Boston IPO revival mean for the region’s life-sciences job market?